strategy
Addex is seeking to develop and market breakthrough products for important therapeutic indications. As a result, for the foreseeable future, most of the company's products will be partenered. This is because Addex believes it is best to realize the commercial opportunity for its products through partnerships with large companies that have the necessary infrastructures to develop and sell drugs for large therapeutics indications.
Because discovery and development of allosteric modulators for GPCRs is such a new approach, it is allowing Addex to be opportunistic and pursue low hanging fruit. Specifically, the company is able to generate novel chemical entities that act on clinically and commercially validated targets.
Currently Addex is performing four screenings per year for new allosteric modulators against the targets of its choosing. The pipeline demonstrates that the company's capabilities are applicable to a broad array of GPCR targets with relevance in multiple major indications.
In order to make the most of its resources while taking the least risk, the company plans to advance to clinical proof of concept products for which the development path is known to be fast and relatively inexpensive. In other words, the orally available small molecule GLP1R PAM can be tested through to the end of Phase II clinical proof of concept by Addex alone because the trials are predictive, quick and inexpensive, requiring only standard diagnostics on blood samples.
In contrast, for products with more complicated, longer development timelines and where the target is not clinically validated, like for ADX63365 in schizophrenia or mGluR4 PAM in Parkinson's disease, Addex' strategy is to establish collaborations to diffuse the associated risk and expense. Areas outside of our core interests in CNS, metabolic disorders and inflammation, like FSHR NAM for contraception, also may be partnered prior to clinical proof of concept.
